Skip to main content

Table 5 Adjusted incidence rate ratios and 95% confidence intervals for factors associated with AIDS-related events, non-AIDS-related events, and deaths (ANRS CO3 Aquitaine and IPEC/FIOCRUZ cohorts combined, 20002008)

From: AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies

  AIDS-related Non-AIDS
   All Bacterial Psychiatric Hepatic
Cohort: IPEC (vs. Aquitaine) 1.09 (0.91, 1.3) 0.53 (0.46, 0.62) 1.17 (0.94, 1.47) 0.37 (0.24, 0.55) 0.78 (0.52, 1.17)
Calendar year (per year) 1.03 (0.99, 1.06) 1.02 (1.0, 1.05) 1.03 (1.0, 1.07) 1.04 (0.98, 1.09) 1.05 (0.98, 1.12)
Age (in years)      
<30 years 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
30-39 0.95 (0.72, 1.26) 1.05 (0.83, 1.33) 1.34 (0.98, 1.83) 1.28 (0.76, 2.17) 0.8 (0.39, 1.65)
40-49 0.81 (0.61, 1.08) 1.12 (0.88, 1.44) 1.18 (0.85, 1.64) 1.18 (0.7, 2.01) 1.52 (0.78, 2.99)
50-59 0.59 (0.42, 0.83) 1.24 (0.94, 1.65) 1.13 (0.78, 1.64) 0.95 (0.5, 1.78) 1.48 (0.67, 3.28)
≥60 0.93 (0.61, 1.4) 2.16 (1.58, 2.97) 1.9 (1.24, 2.89) 1.14 (0.54, 2.38) 3.09 (1.13, 8.49)
Sex: Female (vs. Male) 0.9 (0.76, 1.07) 1.01 (0.88, 1.15) 0.95 (0.79, 1.15) 1.06 (0.81, 1.37) 0.98 (0.63, 1.52)
IDU: Yes (vs. No) 1.03 (0.78, 1.36) 1.42 (1.18, 1.7) 1.01 (0.75, 1.34) 3.14 (2.29, 4.3) 1.49 (0.89, 2.49)
CD4 cell count (cells/mm3)      
>500 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
351-500 3.47 (2.19, 5.51) 1.28 (1.07, 1.53) 1.24 (0.95, 1.61) 0.96 (0.67, 1.38) 2.42 (1.44, 4.08)
201-350 9.05 (5.91, 13.88) 2.25 (1.89, 2.67) 1.85 (1.43, 2.4) 1.98 (1.44, 2.73) 4.87 (2.97, 7.99)
51-200 31.83 (20.81, 48.71) 4.34 (3.59, 5.24) 3.94 (2.95, 5.26) 2.59 (1.76, 3.79) 9.52 (5.56, 16.29)
≤50 111.45 (70.13, 177.11) 10.99 (8.66, 13.94) 9.14 (6.37, 13.12) 4.98 (2.96, 8.37) 22.31 (11.27, 44.15)
HIV viral load (copies/mL)      
≤400 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
401-3000 1.58 (1.14, 2.17) 1.3 (1.09, 1.54) 1.41 (1.09, 1.83) 1.08 (0.75, 1.57) 1.28 (0.76, 2.17)
3001-10000 1.6 (1.11, 2.29) 1.45 (1.18, 1.76) 1.12 (0.83, 1.52) 1.87 (1.25, 2.81) 1.71 (0.86, 3.4)
10001-100000 2.3 (1.76, 3.01) 1.76 (1.5, 2.06) 1.96 (1.54, 2.49) 2.02 (1.44, 2.84) 1.53 (0.96, 2.43)
>100000 4.39 (3.33, 5.8) 2.61 (2.15, 3.16) 2.79 (2.12, 3.68) 2.89 (1.93, 4.33) 2.18 (1.21, 3.92)
≤1 year since HIV + test: Yes (vs. No) 3.87 (3.19, 4.71) 1.99 (1.69, 2.35) 1.51 (1.16, 1.97) 1.04 (0.65, 1.67) 2.74 (1.84, 4.1)
On cART: Yes (vs. No) 2.15 (1.23, 3.74) 2.5 (1.82, 3.44) 1.58 (1.04, 2.41) 2.21 (1.12, 4.38) 3.72 (1.5, 9.2)
Hepatitis B positive (vs. not) 1.03 (0.77, 1.39) 1.17 (0.93, 1.47) 1.23 (0.9, 1.68) 0.92 (0.57, 1.5) 1.93 (1.16, 3.18)
Hepatitis C positive (vs. not) 0.95 (0.74, 1.23) 1.7 (1.45, 2.0) 1.91 (1.52, 2.4) 1.73 (1.29, 2.32) 5.18 (3.29, 8.14)
  Non-AIDS Death
  Viral Neurological Cardiovascular Parasitic  
Cohort: IPEC (vs. Aquitaine) 0.52 (0.38, 0.7) 0.06 (0.03, 0.12) 1.13 (0.76, 1.68) 0.17 (0.09, 0.3) 1.01 (0.79, 1.28)
Calendar year (per year) 0.95 (0.9, 1.0) 0.96 (0.9, 1.02) 1.01 (0.94, 1.1) 1.04 (0.98, 1.11) 1 (0.96, 1.04)
Age (in years)      
<30 years 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
30-39 0.93 (0.6, 1.44) 1.1 (0.55, 2.21) 0.93 (0.39, 2.19) 1.07 (0.59, 1.94) 1.76 (0.92, 3.35)
40-49 0.82 (0.51, 1.31) 1.41 (0.67, 2.93) 1.72 (0.74, 4) 0.89 (0.48, 1.65) 2.18 (1.15, 4.14)
50-59 0.76 (0.44, 1.32) 1.55 (0.72, 3.33) 2.4 (0.99, 5.81) 0.85 (0.43, 1.67) 3.25 (1.69, 6.25)
>60 0.94 (0.47, 1.85) 3.13 (1.41, 6.97) 5.27 (2.14, 12.93) 1.19 (0.42, 3.35) 6.55 (3.32, 12.92)
Sex: Female (vs. Male) 1.26 (0.98, 1.62) 1.04 (0.74, 1.47) 0.94 (0.65, 1.35) 1.2 (0.85, 1.69) 0.66 (0.51, 0.85)
IDU: Yes (vs. No) 1.07 (0.77, 1.48) 2.01 (1.29, 3.12) 1.55 (0.97, 2.46) 1.08 (0.71, 1.64) 1.29 (0.93, 1.78)
CD4 cell count (cells/mm3)      
>500 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
351-500 0.81 (0.55, 1.18) 1.48 (0.94, 2.33) 2.00 (1.23, 3.24) 1.79 (0.85, 3.75) 1.44 (0.99, 2.08)
201-350 1.76 (1.25, 2.48) 2.3 (1.52, 3.46) 2.06 (1.22, 3.47) 3.82 (1.88, 7.76) 2.25 (1.6, 3.18)
51-200 2.8 (1.9, 4.11) 5.76 (3.58, 9.26) 4.64 (2.66, 8.12) 11.73 (5.9, 23.32) 6.33 (4.5, 8.89)
≤50 9.71 (6.07, 15.52) 13.6 (7.55, 24.49) 15.9 (8.13, 31.28) 29.59 (13.83, 63.28) 27.32 (18.44, 40.47)
HIV viral load (copies/mL)      
≤400 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
401-3000 1.38 (0.94, 2.02) 1.51 (0.98, 2.33) 0.91 (0.52, 1.59) 2.22 (1.11, 4.48) 0.91 (0.64, 1.31)
3001-10000 1.65 (1.07, 2.53) 1.91 (1.23, 2.97) 1.13 (0.6, 2.1) 3.09 (1.52, 6.31) 1.03 (0.68, 1.56)
10001-100000 2.52 (1.83, 3.46) 1.63 (1.11, 2.38) 1.18 (0.77, 1.8) 4.88 (2.9, 8.21) 1.08 (0.81, 1.44)
>100000 3.13 (2.1, 4.65) 2.49 (1.59, 3.9) 1.15 (0.67, 1.99) 8.03 (4.51, 14.29) 1.49 (1.07, 2.09)
≤1 year since HIV + test: Yes (vs. No) 2.72 (1.93, 3.83) 1.17 (0.67, 2.03) 1.67 (0.96, 2.93) 4.51 (3.14, 6.47) 0.85 (0.53, 1.37)
On cART: Yes (vs. No) 2.45 (1.3, 4.6) 8.3 (1.95, 35.33) 3.86 (1.17, 12.8) 7.62 (1.75, 33.26) 0.85 (0.5, 1.47)
Hepatitis B positive (vs. not) 0.98 (0.61, 1.59) 1.07 (0.6, 1.91) 1.05 (0.61, 1.8) 1.31 (0.73, 2.37) 1.96 (1.44, 2.66)
Hepatitis C positive (vs. not) 1.11 (0.82, 1.51) 1.02 (0.65, 1.58) 1.31 (0.89, 1.94) 1.26 (0.85, 1.87) 1.79 (1.34, 2.38)
  1. Bold indicates statistically significant results.
  2. IDU injection drug use. cART combination antiretroviral therapy.